Cyclopharm Limited CYC-Financial and Strategic SWOT Analysis Review

Cyclopharm Limited CYC-Financial and Strategic SWOT Analysis Review

  • Products Id :- GDPH82495FSA
  • |
  • Pages: 41
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Cyclopharm Limited (CYC)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Cyclopharm Limited(Cyclopharm) is a radiopharmaceutical company which manufactures medical and healthcare equipment and components in the nuclear medicine business. The company's products include Technegas, a lung imaging device used to diagnose the presence of blood clots in the lungs; and positron emission tomography (PET) radiopharmaceuticals. The company is evaluating Technegas in new indications such as chronic obstructive pulmonary disease (COPD) and lung cancer. The company operates a joint venture, Macquarie Medical Imaging, which provides diagnostic imaging services such as 3T MRI, CT, X-ray, ultrasound and positron emission tomography (PET) scanning. Cyclopharm harnesses its Ultralute technology, which extends the life of Molybdenum-99 generators. The company operates in Asia Pacific, Canada, Latin America, Europe and Germany. Cyclopharm is headquartered in New South Wales, Australia.

Cyclopharm Limited Key Recent Developments

Feb 24, 2016: Cyclopharm: Strong Technegas Earnings Underpin Record Profit

Oct 12, 2015: Australian company Cyclopharm launches world-first nuclear medicine technolog

Feb 19, 2015: Cyclopharm Reports Record Profit

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Cyclopharm Limited-Key Facts 6

Cyclopharm Limited-Key Employees 7

Cyclopharm Limited-Key Employee Biographies 8

Cyclopharm Limited-Key Operational Employees 9

Cyclopharm Limited-Major Products and Services 10

Cyclopharm Limited-History 11

Cyclopharm Limited-Company Statement 13

Cyclopharm Limited-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Joint Venture 16

Section 2-Company Analysis 17

Cyclopharm Limited-Business Description 17

Cyclopharm Limited-Corporate Strategy 18

Cyclopharm Limited-SWOT Analysis 19

SWOT Analysis-Overview 19

Cyclopharm Limited-Strengths 19

Strength-Growth in Technegas Segment 19

Strength-Research and Development Activities 19

Strength-Operational Base 19

Cyclopharm Limited-Weaknesses 20

Weakness-Declined Molecular Imaging Segment 20

Weakness-Decrease in Canada Geographic Segment 20

Cyclopharm Limited-Opportunities 21

Opportunity-Global Diagnostic Imaging Market 21

Opportunity-Growing Aged Population 21

Opportunity-Business Initiatives 21

Cyclopharm Limited-Threats 22

Threat-Intense Competition 22

Threat-Uncertain R&D Outcomes 22

Threat-Rapid Technological Changes 22

Cyclopharm Limited-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 27

Financial Performance 27

Financial Ratios-Interim Ratios 28

Financial Ratios-Ratio Charts 29

Section 4-Company's Lifesciences Financial Deals and Alliances 30

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 31

Cyclopharm Limited, Recent Deals Summary 32

Section 5-Company's Recent Developments 33

Feb 24, 2016: Cyclopharm: Strong Technegas Earnings Underpin Record Profit 33

Oct 12, 2015: Australian company Cyclopharm launches world-first nuclear medicine technolog 35

Feb 19, 2015: Cyclopharm Reports Record Profit 36

Section 6-Appendix 37

Methodology 37

Ratio Definitions 37

About GlobalData 41

Contact Us 41

Disclaimer 41

List of Figures

Cyclopharm Limited, Performance Chart (2011-2015) 27

Cyclopharm Limited, Ratio Charts 29

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 31

List of Tables

Cyclopharm Limited, Key Facts 6

Cyclopharm Limited, Key Employees 7

Cyclopharm Limited, Key Employee Biographies 8

Cyclopharm Limited, Key Operational Employees 9

Cyclopharm Limited, Major Products and Services 10

Cyclopharm Limited, History 11

Cyclopharm Limited, Subsidiaries 15

Cyclopharm Limited, Joint Venture 16

Cyclopharm Limited, Key Competitors 23

Cyclopharm Limited, Ratios based on current share price 24

Cyclopharm Limited, Annual Ratios 25

Cyclopharm Limited, Interim Ratios 28

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 30

Cyclopharm Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 31

Cyclopharm Limited, Recent Deals Summary 32

Currency Codes 37

Capital Market Ratios 37

Equity Ratios 38

Profitability Ratios 38

Cost Ratios 39

Liquidity Ratios 39

Leverage Ratios 40

Efficiency Ratios 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

China Renji Medical Group Limited

PETNET Solutions

Agenix Limited

Optiscan Imaging Limited

Cyclopharm Limited, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 300 INR 20235
Site License
USD 600 INR 40470
Corporate User License
USD 900 INR 60705



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]